Recombinant Human FAP (N-8His)

Recombinant Human FAP (N-8His)

Size1:10μg price1:$168
Size2:50μg price2:$465
Size3:500μg price3:$2550
SKU: PHH2371 Category: Target Proteins Tags: ,

Datasheet

Name

Recombinant Human FAP (N-8His)

Purity

Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level

<1 EU/µg as determined by LAL test.

Construction

Recombinant Human Prolyl endopeptidase FAP is produced by our Mammalian expression system and the target gene encoding Leu26-Asp760 is expressed with a 8His tag at the N-terminus.

Accession #

Q12884

Host

Human Cells

Species

Human

Predicted Molecular Mass

86.1 KDa

Buffer

Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 20% Glycerol, pH 8.0.

Form

Liquid

Shipping

The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

 

 

 

Alternative Names

FAP; FAPA; DPPIV; SIMP; Fapalpha

 

Background

FAP (also known as seprase) is a single-pass type II membrane protein which belongs to thepeptidase S9B family. FAP appears to act as a proteolytically active 170-kDa dimer, consisting of two 97-kDa subunits. It is a member of the group type II integral serine proteases, which includes dipeptidyl peptidase IV ( DPPIV / CD26 ) and related type II transmembrane prolyl serine peptidases, which exert their mechanisms of action on the cell surface. FAP is also an endopeptidase that can degrade Gelatin, Collagens I and IV, Fibronectin, and Laminin as well as several peptide hormones. The enzymatic activity is dependent on FAP association with DPPIV on the cell surface. The matrix-dedgrading activity of FAP contributes to tumor cell migration and invasion. In addition, FAP can enhance tumor cell growth by limiting the development of anti-tumor immunity.

 

Note

For Research Use Only , Not for Diagnostic Use.